advanced search
2022_June_OMPS_Aidaptus_leaderboard

FORMULATION

ADDRESSING THE CHALLENGES OF VISCOUS INJECTABLE ADMINISTRATION
EXPERT VIEW
Dr Andrew Donnelly
ADDRESSING THE CHALLENGES OF VISCOUS INJECTABLE ADMINISTRATION
Andrew Donnelly and Shahid Uddin look at the challenges of self-administration of injectable viscous formulations and the technology that is helping to overcome these issues.
COMPARATIVE EXTRACTABLE STUDIES FOR INJECTABLES AND MEDICAL DEVICES ALIGNED WITH USP <1663> AND ISO 10993 GUIDELINES
INJECTION
Dr Matthias Bicker
SCHOTT Pharma
COMPARATIVE EXTRACTABLE STUDIES FOR INJECTABLES AND MEDICAL DEVICES ALIGNED WITH USP <1663> AND ISO 10993 GUIDELINES
Matthias Bicker, Michael Müller, Marc Mittermüller, Daniel Haines and Uwe Rothhaar discuss the regulatory requirements that need to be considered when designing an extractables and leachables study for a drug product or medical device. To illustrate the subject further, the authors provide two example studies, each following a different set of regulatory guidelines.
INTERVIEW WITH BENJAMIN DIETIKER, WEIDMANN MEDICAL TECHNOLOGY
INTERVIEW
Benjamin Dietiker
INTERVIEW WITH BENJAMIN DIETIKER, WEIDMANN MEDICAL TECHNOLOGY
Benjamin Dietiker, Weidmann Medical Technology, talks with ONdrugDelivery about how the company has successfully implemented a growth strategy by focusing on key areas, plans for expansion, the effect of covid-19 on the business, and how the company differentiates itself from larger competitors by focusing on quality and service.
ROOM FOR INNOVATION?
EXPERT VIEW
Darren Mansell
ROOM FOR INNOVATION?
Darren Mansell examines US FDA guidance on biosimilar interchangeability and asks whether there is room for innovation.
NANOTECHNOLOGY: A PATHWAY FOR SUSTAINABLE INNOVATION IN DRUG DEVELOPMENT
SUSTAINABILITY
Andrea Cusack
leon-nanodrugs
NANOTECHNOLOGY: A PATHWAY FOR SUSTAINABLE INNOVATION IN DRUG DEVELOPMENT
Andrea Cusack discusses how, by using bottom-up nanotechnology techniques, efficiencies can be found both in the development of new chemical entities and in the repurposing of existing drugs, and how these efficiencies translate into reduced energy requirements and therefore more sustainable industry practices.
FROM FORMULATION TO MANUFACTURING: LIPID NANOPARTICLE mRNA VACCINES, GENE THERAPIES & OTHER NANOMEDICINES
INDUSTRIALISATION
Stephen Allan
Evonik
FROM FORMULATION TO MANUFACTURING: LIPID NANOPARTICLE mRNA VACCINES, GENE THERAPIES & OTHER NANOMEDICINES
Stephen Allan reviews the history and formulation advantages of lipid nanoparticles (LNPs) and addresses factors that should be considered by pharmaceutical companies during the CDMO selection process to help reduce regulatory risk, improve product performance and accelerate speed to market.
SILICA RE-EMERGES AS POTENTIAL NUCLEIC ACID DELIVERY VECTOR
EXPERT VIEW
Nigel Theobald
SILICA RE-EMERGES AS POTENTIAL NUCLEIC ACID DELIVERY VECTOR
Nigel Theobald looks at the challenges of oligonucleotide delivery and explores approaches to overcome them.
MedinCell investigating role of long-acting antivirals to break chain of SARS-COV-2 viral transmission
MedinCell investigating role of long-acting antivirals to break chain of SARS-COV-2 viral transmission
With evidence indicating that the established antiparasitic ivermectin can kill coronavirus in a laboratory setting in under 48 hours, MedinCell has published data showing that long-acting formulations of ivermectin can be designed with varying doses and durations with its BEPO® technology and is investigating whether a long-acting product could be effective in breaking the chain of viral transmission.
Lexaria Bioscience Expands Pharma Division for development of Lipophilic Antivirals against COVID-19
Lexaria Bioscience Expands Pharma Division for development of Lipophilic Antivirals against COVID-19
Lexaria is to investigate how its patented DehydraTECH drug delivery technology could enhance delivery and effectiveness of certain antiviral drugs in the fight against coronavirus disease COVID-19.  Lexaria intends to expand collaboration with leading laboratories as soon as possible.
COMPANY SHOWCASE: Cristal Therapeutics
INJECTION
Dr Cristianne Rijcken
COMPANY SHOWCASE: Cristal Therapeutics
Over the past year, Cristal Therapeutics has transitioned from a research-stage start-up to a fully fledged, clinical-stage business with a promising pipeline of proprietary drug candidates. This diverse pipeline together with the proprietary nanoparticle platform, CriPec®, presents a broad range of promising late- and early-stage partnering opportunities for companies active in the oncology space.
ENABLING SUBCUTANEOUS DELIVERY OF BIOLOGICS
INJECTION
Elektrofi
ENABLING SUBCUTANEOUS DELIVERY OF BIOLOGICS
Elektrofi introduces Elektroject™, a gentle process for the production of ultra-high concentration protein formulations, that maintains a syringeable format and excellent protein stability, making the switch from intravenous to subcutaneous delivery viable for numerous biotherapeutics, including monoclonal antibodies.
Top